ArticleScientific reports2025
Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive malignancy lacking effective therapeutic strategies, resulting in a poor patient prognosis. In this study, we investigated the efficacy and underlying molecular mechanisms of the combination of FAK inhibitor Ifebemtinib and paclitaxel in TNBC. We found that FAK were significantly upregulated in breast cancer and correlated with poor prognosis in both breast cancer and TNBC patients. In vitro, the combination of Ifebemtinib and paclitaxel synergistically suppressed proliferation and colony-formation of TNBC cells. Through inactivating CDK1, they induced cell cycle arrest at G2/M phase. By down-regulating Bcl-2 and up-regulating Bax, the combination induced triggered apoptosis. By up-regulating E-cadherin, down-regulating N-cadherin and vimentin, they inhibited migration of TNBC cells. In vivo, the combination inhibited TNBC cell proliferation and spontaneous lung metastasis. Mechanistically, on one hand, the combination synergistically inhibited phosphorylation-mediated activation of FAK. On the other hand, they downregulated LSD1, thereby relieving LSD1-mediated transcriptional repression of PIK3IP1, which is a negative regulator of the PI3K/Akt pathway, leading to accumulation of PIK3IP1. By inhibiting FAK activation and upregulating PIK3IP1, Ifebemtinib and paclitaxel blocked the PI3K/Akt pathway, effectively suppressing TNBC proliferation and metastasis. Our findings suggest that FAK may serve as a potential therapeutic target for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.